Innovative nanotechnological RNA delivery systems targeting the direct cause of Alzheimer‘s disease instead of its symptoms

Neurodegenerative diseases such as Alzheimer’s affect over 7 million people in Europe. Despite this fact, few treatments for this group of diseases are available so far. Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain.

Therefore, the multinational research project B-SMART sets out to provide an RNA-based therapy perspective for neurodegenerative diseases targeting the direct cause of the disease instead of its symptoms in the midterm.

Photo of Prof. Raymond Schiffelers

"Transferring RNA therapeutics to the brain crossing the blood-cerebrospinal fluid barrier is a unique research endeavor. Finding a novel gateway to transport RNA to the brain will enable the development of causal therapies not only for Alzheimer’s, but for other diseases as well." Prof. Raymond Schiffelers (UMCU), Coordinator of B-SMART

News & Events

Neurodegenerative Diseases
Icon 1

Lack of causal therapies and effective drugs

Nanomedicines
Icon 2

RNA-based nanomedicines directly targeting the brain

Transport
Icon 3

Secure in-vivo transport through nanocarriers

Delivery
Icon 4

Crossing the blood-cerebrospinal fluid barrier through ligands

Proof of Concept
Icon 5

Basis technology for treatment of other diseases